Stymied by FDA regulators, GPC Biotech has pulled its application for satraplatin, an experimental therapy for prostate cancer. Regulators demanded to see more data on the drug before they could make a final decision, and GPC now plans to wait until a late-stage trial is complete before resubmitting. Data from the Phase III trial is expected in six months.
- read the report from Hemscott
GPC cancer drug voted down by FDA committee. Report
FDA questions satraplatin. Report
Phase III data backs Satraplatin for prostate cancer. Report
GPC posts positive satraplatin data. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report